Travere Therapeutics (TVTX) stock, explained like you're 5

Is Travere Therapeutics a small, medium or large cap company?

No. Travere Therapeutics is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 4.9 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Travere Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves TVTX stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history (Yahoo Finance UK)
• TVTX Stock On Track To Hit Near 20 Year Highs After Filspari Becomes The Only Approved FSGS Treatment (Stocktwits)
• An officer proposes selling 243,735 shares at Travere Therapeutics (TVTX). (Stock Titan)
• Learn Why The Bull Case For Travere Therapeutics Stock Could Change Following FILSPARI Kidney Data (Simply Wall Street)
• Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Key terms to know before you follow TVTX

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility